DontBadgerMe
Posted - 1 week ago
$NDRA $VKTX $MDGL $ICPT go to the Echosens website.and look at the global FibroScan locator and you'll see how far behind Endra is
BearBullyJack
Posted - 1 week ago
$NDRA can someone get me up to speed? Had an investment in this 4 years ago and sold after a small gain because wasn’t getting the price movement I was hoping for from positive results from $VKTX $MDGL, and at the time $ICPT. What reason has this not taken off? Approval in EU, alternative to biopsies? Faster diagnosis? I just can’t wrap my mind around it but maybe someone can get me up to speed as I have not followed it for years now. Looking to jump back in, thanks
TraderLawJCF
Posted - 1 week ago
$MDGL Where’s the fraud CEO of $ICPT from 2014 thinking he had miracle rejecting b/o offers…selling shared every year…on his yacht
BearBullyJack
Posted - 1 week ago
$MDGL $VKTX I’ve seen these guys grow nearly from their infancy. My conviction has remained strong through and through and given the data provided over the last few years and in comparison to others in this space, particularly $ICPT FDA review, Madrigal will surely be approved and sell well. Viking will have a good chance to share that market share and be a menace when it too reaches the market for sales but Madrigal has a solid 2 years to make a mark in their market share and get real sale numbers up. Hold strong folks, this one has room to grow $400+ and Viking at $150+ especially given their GLP-1 and the not so known but absolutely freakishly good drug VK5211
rencofilstat
Posted - 2 weeks ago
$ICPT Go fail another FDA trial due to safety.
rencofilstat
Posted - 2 weeks ago
$ICPT sucks ass farts.
All_just_a_game
Posted - 3 weeks ago
$MDGL This is from 2016 when I acquired my MDGL stake via Synta. Thank god Becky was shagging Paul and they merged companies otherwise I would have been a permanent bankrupt bag holder. 8 years later.. ICPT GILD Genfit. Failed. Madrigal..2 weeks from being only approved therapy. ☘️ ☘️☘️☘️☘️☘️GL
After PhIII failure Synta announces merger, shifts R&D focus
By Ben Adams
Apr 14, 2016 9:53am
Synta joins a long and growing list of biotechs and pharma moving in on the NASH space, which analysts believe could be worth $40 billion in the next decade.
Intercept ($ICPT), Gilead ($GILD) and French biotech Genfit are just some of the players in this emerging field which aim to develop the first ever treatments for the liver scarring disease--a disease caused predominately by the rising rates of obesity and diabetes.
Stock_Titan
Posted - 02/29/24
$ICPT Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC https://www.stocktitan.net/news/ICPT/intercept-announces-fda-acceptance-of-supplemental-new-drug-r05mdkc22mni.html
GSMITH10107
Posted - 1 month ago
$IVA is it possible $IVA could potentially be the leader in NASH ? i know $ICPT got bought out and $MDGL is launching this year, but thsi graphic has to mean alot..
GSMITH10107
Posted - 1 month ago
$IVA 194 million dollar market cap.. well into phase 3 compared to NASH players $ICPT bought out for 795 million $MDGL 4.1 billion $AKRO 1.1 billion pretty shocking graphic if you ask me when do i get my correction?
MMCT
Posted - 1 month ago
$MDGL @@All_just_a_game @CC_Abbott Could u both point out on a comment why $ICPT got rejected by Adcom and why We have a better chance 😄
bbear
Posted - 1 month ago
$ICPT never forget some assclown at BOA slapped a $800 PT on this in 2014. she then left BOA to work for the company.
tickeron
Posted - 2 months ago
$ICPT $ATXS $CBAY $CBAY, $ARDX, $VKTX Lead Biotech Sector Surge with Remarkable +10.76% Weekly Performance Gain. Robots for this group tickers : Swing Trader, Long Only: Growth Model (FA) - 30-day Annualized Return +77% Swing Trader for.... https://srnk.us/go/4967249
ChartMill
Posted - 2 months ago
Besides having an excellent technical rating, $ICPT also presents a decent setup pattern.
https://www.chartmill.com/stock/quote/ICPT/technical-analysis?key=bdeece9e-091e-4ba6-8f28-cd4984a41b41&utm_source=SETUP&utm_medium=stocktwits&utm_campaign=TA&utm_content=ICPT
tickeron
Posted - 2 months ago
$ICPT $ATXS $CBAY $ATXS, $CBAY, $ARDX, $VKTX: Metabolic Biotech Stocks Surge 10.24% in a Week. Robots for this group tickers : Swing Trader, Long Only: Growth Model (FA) - 30-day Annualized Return +71% Trend Trader,.... https://srnk.us/go/4965250
US_Bull
Posted - 3 months ago
$ICPT People were saying the exact same thing on the ICPT (Mciced can confirm) daily no sound crickets and boom make no mistake same thing will happen here. BP would have to be outright stupid not to want LUP in their portfolio a potential 7-800 million drug in the right hands it is basically given easy money and our patent portfolio is iron clad strong (no one would dare challenge it again). Just patience. SP is slowly getting to a level where BO can reach a fair level 22-26$ should do the trick.
YasmyGuy
Posted - 3 months ago
@Gymnut $XCN.X $ICPT Cho Cho! Not selling either!!!
MarketBeat
Posted - 3 months ago
Intercept Pharmaceuticals initiated by StockNews.com at hold. www.marketbeat.com/stocks/NASDAQ/ICPT/price-target/ $ICPT
thePistolPete
Posted - 3 months ago
$ICPT the glory days
75guyjax
Posted - 3 months ago
$ICPT sugar pill??? Why slander, sir??
cctranscripts
Posted - 4 months ago
Securities registration termination [Section 12(g)] https://www.conferencecalltranscripts.org/summary/?id=12723554 $ICPT
stockilluminati
Posted - 4 months ago
$ICPT https://www.stockilluminati.com/icpt/filings.php - Intercept Pharmaceuticals, Inc. - Common Stock files form 15-12G today, check out the details.
stockilluminati
Posted - 4 months ago
$ICPT https://www.stockilluminati.com/icpt/news.php - Circling Back On CymaBay Therapeutics
tickeron
Posted - 4 months ago
Intercept Pharmaceuticals to report earnings on November 13, 2023. Earnings per share (EPS) estimate: $-0.23 $ICPT https://srnk.us/go/4913828
Stock_Titan
Posted - 4 months ago
$ICPT Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023
https://www.stocktitan.net/news/ICPT/intercept-announces-new-phase-2-data-showing-significant-impact-of-33xujuhzywti.html
neelsen01
Posted - 4 months ago
$CHRS With this disappointing quarter revenue release, and foreseeing ASP pressure on biosimilars over the next couple years, this company may very well end up like $ICPT…
tickeron
Posted - 4 months ago
$ICPT enters bearish trend https://srnk.us/go/4911537